56
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy

, MD, , MD, , MD, , MBA & , MS
Pages 109-118 | Accepted 09 Jan 2002, Published online: 02 Dec 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Karen Moeremans & Lieven Annemans. (2006) Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opinion on Pharmacotherapy 7:14, pages 1931-1943.
Read now
Winter J Gibbs, Richard H Drew & John R Perfect. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-infective Therapy 3:2, pages 167-181.
Read now

Articles from other publishers (7)

Hongbo Yang, Paresh Chaudhari, Zheng-Yi Zhou, Eric Q. Wu, Chad Patel & David L. Horn. (2014) Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. Applied Health Economics and Health Policy 12:1, pages 85-93.
Crossref
Rolin L. Wade, Paresh Chaudhari, Jaime L. Natoli, Robert J. Taylor, Brian H. Nathanson & David L. Horn. (2013) Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagnostic Microbiology and Infectious Disease 76:3, pages 361-367.
Crossref
Wiro B. Stam, Franco Aversa, Ritesh N. Kumar & Jeroen P. Jansen. (2008) Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. Value in Health 11:5, pages 830-841.
Crossref
John R. Wingard, Helen L. Leather, Craig A. Wood, William C. Gerth, Robert J. Lupinacci, Marc L. Berger & Edward C. Mansley. (2007) Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American Journal of Health-System Pharmacy 64:6, pages 637-643.
Crossref
John R. Wingard, Craig A. Wood, Elizabeth Sullivan, Marc L. Berger, William C. Gerth & Edward C. Mansley. (2005) Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis. Clinical Therapeutics 27:6, pages 960-969.
Crossref
M. M. Prendergrast & K. B. Tong. (2003) Amphotericin B-Related Nephrotoxicity Has an Economic Impact on Hospitals and Health Systems. Clinical Infectious Diseases 37:10, pages 1396-1396.
Crossref
S. Harbarth & M. H. Samore. (2003) Reply. Clinical Infectious Diseases 37:10, pages 1396-1397.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.